Stopping statin treatment early could substantially reduce lifetime protection against heart disease since a large share of the benefit occurs later in life
September 06, 2022
Study Highlights Lifelong Benefits of Statin Therapy
September 6, 2022 — Stopping statin treatment early could substantially reduce lifetime protection against heart…
Read More
Smokers have weaker hearts than non-smokers, according to research
September 06, 2022
Smoking is Even More Damaging to the Heart Than Previously Thought
September 6, 2022 — Smokers have weaker hearts than non-smokers, according to research presented at ESC Congress 2022.1…
Read More
Research presented at ESC Congress 2022 supports a causal relationship between air pollution and heart attacks since smokers, who already inhale smoke, were unaffected by dirty air.
September 06, 2022
Air Pollution is Associated with Heart Attacks in Non-Smokers
September 6, 2022 — Research presented at ESC Congress 2022 supports a causal relationship between air pollution and…
Read More
BOX trial presented in a Hot Line Session at ESC Congress 2022
September 02, 2022
Restrictive Oxygenation in Post Cardiac Arrest Patients is Not Harmful
September 2, 2022 — A restrictive oxygenation target in comatose patients resuscitated after out-of-hospital cardiac…
Read More
DELIVER trial presented in a Hot Line Session at ESC Congress 2022
September 02, 2022
Dapagliflozin Benefits Patients with Mildly Reduced and Preserved Ejection Fraction
September 2, 2022 — Dapagliflozin reduces the risk of cardiovascular death or worsening heart failure in heart failure…
Read More
ADVOR trial presented in a Hot Line Session at ESC Congress 2022
September 02, 2022
Acetazolamide Improves Decongestion in Patients with Acute Decompensated Heart Failure
September 2, 2022 — Acetazolamide added to intravenous loop diuretics decreases congestion within three days in…
Read More
DANCAVAS trial presented in a Hot Line Session at ESC Congress 2022
September 02, 2022
Cardiovascular Screening May Reduce Risk of Death and Cardiovascular Disease
September 2, 2022 — A randomized trial in more than 45,000 men has suggested that cardiovascular screening including …
Read More
DANFLU-1 trial presented in a Hot Line Session at ESC Congress 2022
September 02, 2022
Innovative Randomized Trial Hints at Mortality Benefits with High-Dose Influenza Vaccines
September 2, 2022 — In an innovative, pragmatic randomized trial, high-dose influenza vaccination in older adults was…
Read More
Figure: EchoNet-RCT trial design
September 02, 2022
Artificial Intelligence Assessment of Heart Function is Superior to Sonographer Assessment
September 2, 2022 — In patients undergoing echocardiographic evaluation of cardiac function, preliminary assessment by …
Read More
REVIVED-BCIS2 trial presented in a Hot Line Session today at ESC Congress 2022
September 02, 2022
Coronary Stenting Does Not Benefit Patients with Severe Left Ventricular Dysfunction
September 2, 2022 — Percutaneous coronary intervention (PCI) does not reduce all-cause mortality or heart failure…
Read More
More than 30,271 health professionals from 174 countries attended this year’s event, which covered the entire field of cardiovascular medicine at ESC22
September 01, 2022
Best of ESC Congress 2022
September 1, 2022 — “At ESC Congress in Barcelona, we discussed the newest science in the light of our collective…
Read More
Comatose patients admitted to hospital after resuscitation from out-of-hospital cardiac arrest have a significant risk of death and poor neurological outcome due to hypoxic brain injury.
September 01, 2022
Trial Finds no Benefit of Raising Blood Pressure Target in Post Cardiac Arrest Patients
September 1, 2022 — A target blood pressure of 77 mmHg provides no benefit to survival or neurological outcome in…
Read More
ALL-HEART trial presented in a Hot Line Session at ESC Congress 2022
September 01, 2022
Allopurinol Does Not Improve Cardiovascular Outcomes in Ischaemic Heart Disease Patients
September 1, 2022 — The gout medicine allopurinol has failed to reduce the primary endpoint of nonfatal myocardial…
Read More
BioIntelliSense's new BioButton for 90-days of continuous wireless temperature and vital signs monitoring on a coin-sized disposable medical device
August 31, 2022
Medtronic Announces Partnership with BioIntelliSense for Exclusive U.S. Distribution of Multi-Parameter Wearable for Continuous Remote Patient Monitoring from in-Hospital to Home 
August 31, 2022 — Medtronic plc, a global leader in healthcare technology, announced it has entered into a strategic…
Read More
Healthcare providers should promote prevention of atrial fibriliation, an abnormal heart rhythm disturbance, and early interventions among both female and male patients, say Cedars-Sinai investigators. Photo by Getty Images.
August 31, 2022
Gender Differences and AFib: New Study Flips Conventional Wisdom
August 31, 2022 — Science has long shown that men are at greater risk for developing atrial fibrillation (AFib) than…
Read More
70-year-old White male patient with weight of 79.8 kg, BMI of 29.3, low cardiovascular risk factors (nonsmoker, no diabetes diagnosis, blood pressure of 120/78). Left: Axial CT image at level of L3 vertebral body. Right: Matching automated segmentation label map. Visceral fat area z score is 1.41, corresponding to the 92nd percentile. Patient experienced both subsequent myocardial infarction and stroke.
August 31, 2022
CT-Derived Body Composition With Deep Learning Predicts Cardiovascular Events
August 31, 2022 — According to ARRS’ American Journal of Roentgenology (AJR), fully automated and normalized body…
Read More
A clinician using Ultrasound Workspace from Philips
August 30, 2022
Philips Spotlights Integrated, Data-Driven Cardiology Solutions at ESC 2022
August 30, 2022 —  Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, will showcase its latest…
Read More
SECURE trial presented in a Hot Line Session today at ESC Congress 2022
August 30, 2022
Polypill Reduces Cardiovascular Events in Heart Attack Patients Compared to Usual Care
August 30, 2022 — A pill containing aspirin and medications to lower lipids and blood pressure more effectively…
Read More
The MOMENTUM 3 study showcases the significant survival benefits of Abbott's heart pump technology, particularly in a patient population with limited therapy options
August 30, 2022
New Data Show Abbott's Heartmate 3 Heart Pump Extends Life Beyond Five Years for Advanced Heart Failure Patients
August 30, 2022 — Abbott announced new late-breaking data that show its HeartMate 3 heart pump extends survival of…
Read More
Late-breaking data presented at ESC Congress 2022 and simultaneously published in The New England Journal of Medicine confirms implant procedure safety and defibrillation success
August 29, 2022
FARXIGA Significantly Reduced the Risk of Cardiovascular Death or Worsening of Heart Failure in Patients with Mildly Reduced or Preserved Ejection Fraction in DELIVER Phase III Trial
August 29, 2022 — Detailed results from the DELIVER Phase III trial showed AstraZeneca’s FARXIGA (dapagliflozin)…
Read More
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now